The objective of this study is to investigate the role of HLA- and KIR-Polymorphisms in determining the risk of infection and the course of the disease.

This study prepares the ground for a research consortium at the TU Dresden that will thoroughly investigate the innate and adaptive immune response to SARS-CoV-2 at a molecular level to identify targets for treatment.

Key inclusion criteria : In- and Outpatients with SARS-CoV-2 infection at University Hospital Dresden and affiliate sites.

Key exclusion criteria : Lack of medical data on COVID-19 course for the cross-sectional study.

Controls : > 100,000 registered DKMS donors matched for sex, age and provenance.

To be assessed for eligibility at TU Dresden : 15,000 – 20,000 patients (pts).

Expected to be analyzed in first stage : 1,000 pts.

Second stage : 4,000 pts.

Third stage : 5,000 pts.

Disease will be classed into asymptomatic/mild infections (no fever, no loss of smell, no complaints requiring symptom relief), moderate flu-like courses without respiratory failure, and severe courses with respiratory failure requiring exogenous oxygen. Disease of patients admitted to hospital will be assessed by chart review. Outpatients will be evaluated in a follow-up telephone interview 4 – 8 weeks after diagnosis. Medical Data will be collected in Electronic Patient Information Systems of the participating hospitals and subsequently transferred to the Study Database ion a standard format.

For more information: johannes.schetelig@ukdd.de